Literature DB >> 28681444

A call to incorporate systems theory and human factors into the existing investigation of harm in clinical research involving healthcare products.

Brian D Edwards1, Bernard Bégaud2, Esther Daemen3, Ioannis Dokas4, Jonathan M Fishbein5, Howard E Greenberg6,7, Alan Hochberg8, Hervé Le Louet9, Jytte Lyngvig10, Nataliya Mogles11, Kathryn Owen12, Christine Prendergast13, Martin Rejzek14, Sophia Trantza15, David J Webb16, Matthew Whalen17, Simon Whiteley18.   

Abstract

This is a joint statement from individual pharmacology and pharmaceutical professionals acting in their own capacity, including members of the Alliance for Clinical Research Excellence and Safety (ACRES) and the International Society of Pharmacovigilance (ISoP). By building on the extensive pharmacological and regulatory investigations that already take place, we are calling for a fuller and more robust systems-based approach to the independent investigation of clinical research when serious incidents of harm occur, starting with first-in-human clinical trials. To complement existing activities and regulations, we propose an additional approach blending evidence derived from both pharmacological and organizational science, which addresses human factors and transparency, to enhance organizational learning and continuous improvement. As happens with investigations in other sectors of society, such as the chemical and aviation sector, this systems approach should be seen as an additional way to understand how problems occur and how they might be prevented in the future. We believe that repetition of potentially preventable and adverse outcomes during clinical research, by failing to identify and act upon all systematic vulnerabilities, is a situation that needs urgent change. As we will discuss further on, approaches based on applying systems theory and human factors are much more likely to improve objectivity and transparency, leading to better system design.
© 2017 The British Pharmacological Society.

Entities:  

Keywords:  first-in-human; human clinical research; human factors; independent investigation; systems engineering

Mesh:

Substances:

Year:  2017        PMID: 28681444      PMCID: PMC5651324          DOI: 10.1111/bcp.13353

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Human error: models and management.

Authors:  J Reason
Journal:  BMJ       Date:  2000-03-18

2.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

Authors:  Ganesh Suntharalingam; Meghan R Perry; Stephen Ward; Stephen J Brett; Andrew Castello-Cortes; Michael D Brunner; Nicki Panoskaltsis
Journal:  N Engl J Med       Date:  2006-08-14       Impact factor: 91.245

3.  Making medicines safer--the need for an independent drug safety board.

Authors:  A J Wood; C M Stein; R Woosley
Journal:  N Engl J Med       Date:  1998-12-17       Impact factor: 91.245

4.  A call to incorporate systems theory and human factors into the existing investigation of harm in clinical research involving healthcare products.

Authors:  Brian D Edwards; Bernard Bégaud; Esther Daemen; Ioannis Dokas; Jonathan M Fishbein; Howard E Greenberg; Alan Hochberg; Hervé Le Louet; Jytte Lyngvig; Nataliya Mogles; Kathryn Owen; Christine Prendergast; Martin Rejzek; Sophia Trantza; David J Webb; Matthew Whalen; Simon Whiteley
Journal:  Br J Clin Pharmacol       Date:  2017-07-19       Impact factor: 4.335

5.  Safety in FIH Trials: A Summary of the Symposium "Fatal Drug Trial in Phase 1: Understanding Risk, Subject Safety, Timelines, and Cost".

Authors:  Howard E Greenberg; Mattheus Thijs van Iersel; Mary L Westrick; William B Smith
Journal:  Ther Innov Regul Sci       Date:  2017-05       Impact factor: 1.778

6.  Implications of the BIA-102474-101 study for review of first-into-human clinical trials.

Authors:  Michael Eddleston; Adam F Cohen; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2016-04       Impact factor: 4.335

7.  Systems analysis of adverse drug events. ADE Prevention Study Group.

Authors:  L L Leape; D W Bates; D J Cullen; J Cooper; H J Demonaco; T Gallivan; R Hallisey; J Ives; N Laird; G Laffel
Journal:  JAMA       Date:  1995-07-05       Impact factor: 56.272

  7 in total
  1 in total

1.  A call to incorporate systems theory and human factors into the existing investigation of harm in clinical research involving healthcare products.

Authors:  Brian D Edwards; Bernard Bégaud; Esther Daemen; Ioannis Dokas; Jonathan M Fishbein; Howard E Greenberg; Alan Hochberg; Hervé Le Louet; Jytte Lyngvig; Nataliya Mogles; Kathryn Owen; Christine Prendergast; Martin Rejzek; Sophia Trantza; David J Webb; Matthew Whalen; Simon Whiteley
Journal:  Br J Clin Pharmacol       Date:  2017-07-19       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.